De-escalating treatment for patients with chronic cancers can be beneficial for overall mental health. Patients with chronic lymphocytic leukemia (CLL) are typically treated with Bruton’s tyrosine kinase inhibitors, or BTKis. Although effective, patients typically...
Patients with cancer in rural or high-poverty areas were associated with the most significant improvements in five-year survival. In 2014, a provision under the Patient Protection and Affordable Care Act (ACA) took effect, allowing...
Cancer survivors profiled over the past 15 years in the AACR Cancer Progress Reports shared updates on their lives and the progress made against cancer.
The second AACR Childhood Cancer Predisposition Workshop gathered experts from around the world to refine surveillance strategies, expanding recommendations to nearly 100 syndromes.
Study found teclistamab-cqyv, an immunotherapy, led to responses in patients with high-risk, heavily pretreated multiple myeloma, including after prior BCMA therapy. Teclistamab-cqyv (Tecvayli), a type of immunotherapy, received accelerated approval from the U.S. Food...
Incidence-based mortality is also projected to increase with disproportionately higher rates for Black women compared with white women. Incidence and mortality rates for most cancer types have been on the decline in the United...
Learn how a Gleason score is calculated to help determine the aggressiveness of prostate cancer, and how it could influence a patient's treatment.
The largest increases were found in breast, colorectal, endometrial, pancreatic, and kidney cancers. Early-onset cancers, or cancers diagnosed in individuals under the age of 50, are rising in the United States. While the exact...
A recently approved first-line therapy and novel insights into optimizing treatment strategies may offer new options for esophageal cancer patients.
After Craig Schumpert learned he had lung cancer that had spread to his brain, bones, and lymph nodes, he started radiation therapy. His oncologist told him he might be eligible for targeted therapy, but...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More